Enlivex Therapeutics (NASDAQ:ENLV) Earns “Buy” Rating from D. Boral Capital

Enlivex Therapeutics (NASDAQ:ENLV)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a report issued on Friday,Benzinga reports. They currently have a $13.00 price target on the stock.

Other equities analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Enlivex Therapeutics in a research report on Tuesday, September 2nd. Wall Street Zen raised shares of Enlivex Therapeutics to a “sell” rating in a research report on Saturday, August 30th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $10.00.

Enlivex Therapeutics Stock Performance

Shares of ENLV opened at $1.07 on Friday. The company has a market cap of $25.31 million, a price-to-earnings ratio of -1.84 and a beta of 0.83. Enlivex Therapeutics has a 1-year low of $0.81 and a 1-year high of $2.10. The company’s fifty day simple moving average is $1.24 and its 200 day simple moving average is $1.10.

Institutional Investors Weigh In On Enlivex Therapeutics

An institutional investor recently raised its position in Enlivex Therapeutics stock. Jane Street Group LLC grew its holdings in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) by 527.4% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 80,759 shares of the company’s stock after acquiring an additional 67,886 shares during the quarter. Jane Street Group LLC owned 0.34% of Enlivex Therapeutics worth $78,000 as of its most recent SEC filing. 1.02% of the stock is currently owned by hedge funds and other institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.